Fernando Rivera Selected Research

XELOX

1/2019	Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
1/2013	Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer.
12/2012	Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
1/2012	Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.
1/2012	First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
5/2009	Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study.
4/2008	Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
4/2008	Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
9/2007	Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fernando Rivera Research Topics

Disease

47	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 01/2006
26	Neoplasms (Cancer) 05/2022 - 06/2007
13	Stomach Neoplasms (Stomach Cancer) 01/2021 - 06/2007
9	Disease Progression 12/2020 - 06/2006
8	Adenocarcinoma 01/2021 - 12/2009
6	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 06/2009
6	Neoplasm Metastasis (Metastasis) 11/2018 - 01/2008
6	Head and Neck Neoplasms (Head and Neck Cancer) 10/2009 - 01/2003
5	Neutropenia 01/2022 - 04/2008
4	Hypertension (High Blood Pressure) 11/2018 - 06/2010
4	Carcinoma (Carcinomatosis) 01/2018 - 01/2007
4	Diarrhea 01/2012 - 09/2007
4	Squamous Cell Carcinoma of Head and Neck 10/2009 - 07/2004
3	Melanoma (Melanoma, Malignant) 05/2022 - 10/2017
3	Microsatellite Instability 01/2022 - 12/2020
3	Sarcoma (Soft Tissue Sarcoma) 01/2017 - 07/2012
3	Hand-Foot Syndrome 01/2012 - 09/2007
2	Fatigue 01/2022 - 01/2021
2	Asthenia 11/2018 - 06/2006
2	Circulating Neoplastic Cells 12/2013 - 01/2012
2	Colonic Neoplasms (Colon Cancer) 12/2012 - 07/2009
2	Rectal Neoplasms (Rectal Cancer) 08/2012 - 09/2006
2	Thrombocytopenia (Thrombopenia) 09/2008 - 06/2006
2	Febrile Neutropenia 04/2008 - 01/2007
1	Urinary Bladder Neoplasms (Bladder Cancer) 05/2022
1	Colitis 01/2022
1	Intestinal Perforation 01/2022
1	Glioblastoma (Glioblastoma Multiforme) 01/2019
1	Dysphonia (Spastic Dysphonia) 11/2018
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2018
1	Breast Neoplasms (Breast Cancer) 01/2018
1	Brain Diseases (Brain Disorder) 08/2017
1	Listeriosis (Listeria Infection) 08/2017
1	Exanthema (Rash) 01/2017
1	Nausea 11/2016
1	Weight Loss (Weight Reduction) 06/2015
1	Anorexia 06/2015

Drug/Important Bio-Agent (IBA)

25	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021 - 01/2006
24	Fluorouracil (Carac)FDA LinkGeneric 12/2020 - 01/2006
17	Bevacizumab (Avastin)FDA Link 11/2021 - 04/2008
15	Leucovorin (Folinic Acid)FDA Link 11/2020 - 01/2006
14	Capecitabine (Xeloda)FDA Link 01/2021 - 09/2007
14	Panitumumab (Vectibix)FDA Link 12/2019 - 11/2010
13	Cisplatin (Platino)FDA LinkGeneric 01/2019 - 01/2003
10	Trastuzumab (Herceptin)FDA Link 01/2021 - 08/2009
10	Cetuximab (Erbitux)FDA Link 12/2020 - 06/2006
10	Irinotecan (Camptosar)FDA LinkGeneric 11/2020 - 01/2006
9	XELOXIBA 01/2019 - 09/2007
6	Biomarkers (Surrogate Marker)IBA 11/2020 - 10/2009
6	Gemcitabine FDA Link 01/2020 - 06/2009
6	ErbB Receptors (EGF Receptor)IBA 01/2018 - 10/2009
4	130-nm albumin-bound paclitaxelIBA 01/2020 - 01/2015
4	Carboplatin (JM8)FDA LinkGeneric 09/2008 - 07/2004
3	NanovaccinesIBA 05/2022 - 08/2017
3	pembrolizumabIBA 01/2022 - 12/2020
3	regorafenibIBA 01/2021 - 05/2015
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 04/2014
3	Monoclonal AntibodiesIBA 01/2017 - 11/2010
3	Vinorelbine (Navelbine)FDA LinkGeneric 07/2008 - 07/2004
2	Biological ProductsIBA 01/2021 - 09/2014
2	Albumin-Bound Paclitaxel FDA Link 01/2019 - 01/2015
2	parsatuzumabIBA 10/2017 - 01/2017
2	VaccinesIBA 10/2017 - 08/2017
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2017 - 01/2013
2	Epidermal Growth Factor (EGF)IBA 01/2017 - 08/2014
2	RamucirumabIBA 12/2016 - 04/2014
2	thiamine triphosphorate (TTP)IBA 09/2007 - 06/2007
2	UracilIBA 01/2007 - 07/2004
1	Peptides (Polypeptides)IBA 05/2022
1	AntibodiesIBA 05/2022
1	GoldIBA 05/2022
1	AntigensIBA 05/2022
1	Bacterial ToxinsIBA 05/2022
1	Listeria monocytogenes hlyA protein (listeriolysin O)IBA 05/2022
1	CytokinesIBA 05/2022
1	Alanine Transaminase (SGPT)IBA 01/2022
1	Biosimilar PharmaceuticalsIBA 11/2021
1	trifluridine tipiracil drug combinationIBA 01/2021
1	AlbuminsIBA 01/2019
1	Complement System Proteins (Complement)IBA 01/2019
1	Antimitotic AgentsIBA 01/2019
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2018
1	Cancer VaccinesIBA 10/2017
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2017
1	InterleukinsIBA 08/2017
1	Extracellular Matrix ProteinsIBA 01/2017
1	Immunoglobulin G (IgG)IBA 01/2017
1	Paclitaxel (Taxol)FDA LinkGeneric 12/2016
1	Pharmaceutical PreparationsIBA 06/2015
1	MicroRNAs (MicroRNA)IBA 09/2014

Therapy/Procedure

33	Drug Therapy (Chemotherapy) 01/2022 - 01/2003
30	Therapeutics 01/2022 - 06/2006
7	Radiotherapy 08/2012 - 07/2004
6	Induction Chemotherapy 01/2012 - 01/2003
3	Chemoradiotherapy 01/2018 - 09/2006
2	Immunotherapy 05/2022 - 01/2019
2	Duration of Therapy 11/2018 - 06/2017
2	Neoadjuvant Therapy 08/2012 - 07/2012
1	Drug Tapering 11/2018
1	Biological Therapy 01/2018